Discovered a little over two decades ago, small interfering RNAs (siRNAs) and microRNAs
(miRNAs) are noncoding RNAs with important roles in gene regulation. They have recently …

With the first RNA interference (RNAi) drug (ONPATTRO (patisiran)) on the market, we
witness the RNAi therapy field reaching a critical turning point, when further improvements in …

Small interfering RNA (siRNA) has emerged as a promising strategy for treating several
“undruggable” genetically impaired conditions. The siRNA-based drugs have opened the …

Cancer is one of the leading non-communicable diseases with highest mortality rates
worldwide. About half of all cancer patients receive radiation treatment in the course of their …

This paper examines a perspective to use newly engineered nanomaterials as effective and
safe carriers for gene therapy of cancer. Three different groups of cationic dendrimers …

The epidermal growth factor receptor (EGFR) is an important anti-tumor target. The
development of novel molecular-targeted anti-tumor drugs that can target the interior of …

The ability of lipid nanoparticles (LNPs) to deliver nucleic acids have shown a great
therapeutic potential to treat a variety of diseases. Here, an optimized formulation of QTsome …

Synthetic polymers, such as dendrimers, play a critical role in pharmaceutical discovery and
development. Advances in the application of nanotechnology in medicine have given rise to …

The application of siRNA in gene therapy is mainly limited because of the problems with its
transport into cells. Utilization of cationic dendrimers as siRNA carriers seems to be a …

Small interfering RNAs (siRNAs) are an attractive new agent with potential as a therapeutic
tool because of its ability to inhibit specific genes for many conditions, including viral …